> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md).
# Synergistic Combinations
WFA is a rational combination partner because it targets resistance biology that many standard therapies do not fully address. That does not mean every mechanistically appealing combination is clinically ready.
Most combination evidence is preclinical. Safety cannot be inferred from synergy alone.
### Chemotherapy combinations
#### Cisplatin and carboplatin in ovarian cancer
This is the strongest chemotherapy combination signal.
WFA plus cisplatin acts synergistically in ovarian cancer models through complementary pressure on ROS handling, DNA damage response, and cancer stem cell survival. In orthotopic mouse models, the combination reduced tumour growth and blocked metastasis more effectively than either agent alone.
A key point is that WFA depleted CSC-enriched populations that cisplatin alone tended to spare or enrich.
#### Paclitaxel in non-small cell lung cancer
WFA plus paclitaxel has shown synergy in NSCLC cell lines and early animal work. The combination reduced proliferation, migration, and invasion more than either agent alone.
#### Doxorubicin and liposomal doxorubicin
The most clinically advanced current trial uses Ashwagandha extract with liposomal doxorubicin in recurrent ovarian cancer. This is relevant but does not isolate purified WFA.
#### Temozolomide and radiotherapy in glioblastoma
In glioblastoma models, WFA has increased radiosensitivity and potentiated cytotoxic stress through `HSP90/Akt/mTOR` disruption and proteostasis effects. This remains early.
#### Oxaliplatin in pancreatic cancer
Cell-line work supports synergy through ROS-mediated suppression of the `PI3K/AKT` axis. Human relevance remains uncertain.
#### Sorafenib in thyroid and hepatocellular cancer
Preclinical work supports synergy, including relevance to ferroptosis and EMT in resistant settings.
### Immunotherapy combinations
#### Anti-PD-L1 therapy
This is the most biologically coherent current combination use case.
WFA induces immunogenic cell death and can raise tumour `PD-L1` through ROS-mediated signalling. In syngeneic mouse models, WFA plus anti-PD-L1 outperformed either treatment alone without added toxicity.
#### Anti-PD-1 therapy
The rationale is similar but less directly tested. Recent review work places WFA among phytochemicals that may improve response in otherwise checkpoint-resistant tumours.
### Targeted therapy combinations
#### mTOR inhibitors
This combination needs caution.
mTOR inhibitors activate `TFEB`, increase lysosomal biogenesis, and can counteract WFA's autophagy-blocking strategy if given at the same time. If both are used, timing separation matters.
#### CDK4/6 inhibitors
Available extract-level interaction data suggests major CYP-mediated pharmacokinetic interactions are unlikely at standard exposure. The more practical concern is overlapping toxicity, especially liver stress and blood count monitoring.
For related context, see [CDK4/6 Options and Supplement Considerations](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations.md).
### Natural compound combinations — scheduling conflicts
Some commonly used compounds can directly undermine WFA's autophagy-blocking effect by activating `TFEB` and restoring lysosomal capacity.
| Compound | Mechanism of conflict | Practical action |
| ------------------------------- | ------------------------------------------------ | -------------------------------------------------------------------- |
| Liposomal or high-dose curcumin | Direct `TFEB` binding independent of mTOR status | Keep out of the active WFA window |
| Resveratrol | `mTOR` inhibition leading to `TFEB` activation | Separate from WFA dosing |
| Quercetin | `TFEB` pathway activation | Separate from WFA dosing |
| Metformin | `AMPK → mTOR → TFEB` axis | Consider timing separation when autophagy blockade is a primary goal |
| Sulforaphane | Direct `TFEB` agonism | Separate from WFA dosing |
#### What about proton pump inhibitors and fasting?
PPIs raise lysosomal pH and may act in the same direction as WFA rather than opposing it.
Fasting is more nuanced. `mTOR` inhibition can activate `TFEB`, but the broader metabolic stress of fasting may still complement WFA by making tumour cells more dependent on the very recycling pathways WFA disrupts.
### Practical take
The best-supported combination settings today are:
* platinum-based ovarian cancer work
* paclitaxel-based NSCLC work
* checkpoint inhibitor sensitisation in lung cancer models
The main scheduling caution is simultaneous use with strong `TFEB` activators when autophagy blockade is the intended mechanism.
### Key references
Kakar S. et al. — cisplatin synergy and ovarian cancer stem cell targeting.\
Saneja A. et al. — paclitaxel combinations in non-small cell lung cancer.\
University of Louisville — ovarian cancer trial of Ashwagandha extract plus liposomal doxorubicin.\
Sarin N. et al. — oxaliplatin and WFA synergy in pancreatic cancer chemoresistance.\
Guo J. et al. — sorafenib-combination context and Nrf2/ferroptosis relevance in withanolide review literature.\
Banerjee S. et al. — checkpoint inhibitor sensitisation in non-small cell lung cancer.\
Wang W. et al. — TFEB-activating natural products and lysosomal regulation.\
Teschke R. et al. — herb-drug interaction and safety review context for *Withania somnifera*.\
Access and availability:\
Source: MCS Formulas, “Withaferin A Pro Liposomal.”\
`50 mg` WFA per capsule. Available via healthcare professional request.\
### In this section
#### Core pages
* [Withaferin A (WFA) in Oncology](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology.md)
* [Evidence Summary](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/anti-cancer-mechanisms.md)
* [Immune Effects](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md)
* [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md)
#### Cancer-type pages
* [WFA Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type.md)
* [Breast Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/breast-cancer.md)
* [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/ovarian-cancer.md)
* [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md)
* [Glioblastoma](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md)
* [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/other-cancer-types.md)
#### Practical pages
* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/pharmacokinetics-and-metabolism.md)
* [Sourcing Quality](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/sourcing-quality.md)
* [Safety, Interactions and WFA Dosing](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md)
* [Hormones — ER-α and Androgens](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/hormones-er-a-and-androgens.md)
* [Terrain Support — Liposomal WFA vs Whole-Plant Ashwagandha](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/terrain-support-liposomal-wfa-vs-whole-plant-ashwagandha.md)
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.